2024-10-27 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**1.  Performance vs. S&P 500 (VOO):**

AbbVie Inc. (ABBV) is a pharmaceutical company that develops and markets a range of drugs, including Humira, a blockbuster treatment for autoimmune diseases. 

Over the period analyzed, ABBV's cumulative return of 146.5% outperformed the S&P 500's (VOO) cumulative return of 135.48%, resulting in a 11.02% difference. This difference is considered a **positive performance** relative to the historical range of performance differences between the two, placing ABBV in the 52.99th percentile (top half) in terms of outperformance.

**2. Recent Price Movement:**

* **Last Close:** $189.65 
* **5-Day Moving Average:** $188.34 
* **20-Day Moving Average:** $192.7
* **60-Day Moving Average:** $193.26

The stock is currently trading below all three moving averages, suggesting a potential short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 38.16
* **PPO:** -0.32
* **Delta_Previous_Relative_Divergence:** -4.46 (Negative) - Suggests a short-term downtrend.
* **Expected Return:** 3.06% 

The RSI indicates that the stock is in oversold territory, suggesting potential for a rebound. The PPO is negative, indicating a weakening momentum. The recent relative divergence suggests that the stock may be heading towards a short-term correction. Despite the recent decline, the expected return of 3.06% suggests a potential for long-term growth.

**4. Recent Earnings and Outlook:**

| Date      | EPS | Expected EPS |
|-----------|-----|--------------|
| 2024-07-25 | 2.65 | 2.57         |
| 2024-04-26 | 2.31 | 2.26         |
| 2024-02-02 | 2.79 | 2.76         |
| 2023-10-27 | 2.95 | 2.86         |
| 2023-07-27 | 2.91 | 2.79         |

AbbVie has consistently exceeded earnings expectations in recent quarters. In the most recent quarter (ending July 25, 2024), the company reported EPS of $2.65, exceeding the estimated EPS of $2.57.

**5. News and Recent Issues:**

* **Recent Earnings News:** Recent earnings news (from sources like Shacknews) are to be analyzed to provide insights into the company's performance and future prospects.
* **Recent Market Outlook:** You can find recent market outlooks and analyst opinions for ABBV on platforms like Finbold. This information can provide valuable insights into the potential for future stock performance. 

**6.  Overall Analysis:**

AbbVie Inc. (ABBV) has exhibited strong long-term performance, exceeding the S&P 500's returns. However, the stock is currently facing some short-term headwinds. The recent price action suggests a potential correction, and technical indicators suggest a possible downtrend. While the company has consistently exceeded earnings expectations in recent quarters, it's essential to consider recent news and analyst opinions to gauge the future outlook for the stock.

**7. Recommendation:**

Given the current market dynamics and the potential for short-term volatility, investors might want to adopt a cautious approach to ABBV. However, the company's strong fundamentals, consistent earnings performance, and potential for long-term growth make it a promising investment option for long-term investors. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. Always conduct thorough research and consult with a financial professional before making any investment decisions. 
